Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.

Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.

Jennifer Dinkel, Evaluate
Media & general questions
     

Latest Media Coverage

Nature Reviews Drug Discovery

FDA new drug approvals in Q1 2020

  In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…

Nature Reviews Drug Discovery

Top companies and drugs by sales in 2019

Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…

Browse the archive

Seeking Alpha

Rebiotix Tries To Get One Up Over Seres

"We're building on three successful phase IIs... they've had one phase II programme that failed, and they have no other ones. What they're choosing to do is really…

Seeking Alpha

Does Roche Have The Hemophilia X Factor?

"I think [Roche's (OTCQX:RHHBY) emicizumab has been shown to be that," Guy Young of the Children's Hospital Los Angeles tells EP Vantage."